NCT02623725View on ClinicalTrials.gov

Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

PHASE2CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

April 14, 2016

Primary Completion Date

November 23, 2016

Study Completion Date

October 28, 2018

Conditions
Dengue FeverDengue Hemorrhagic Fever
Interventions
BIOLOGICAL

CYD Dengue Vaccine (5-dose formulation)

0.5 mL, Subcutaneous

BIOLOGICAL

Placebo, NaCl 0.9%

0.5 mL, Subcutaneous

Trial Locations (5)

984

Investigational Site Number 005, Carolina

62587

Investigational Site Number 004, Temixco

29040-091

Investigational Site Number 001, Vitória

Unknown

Investigational Site Number 002, Bucaramanga

Investigational Site Number 003, Tegucigalpa

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02623725 - Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule | Biotech Hunter | Biotech Hunter